Gladius Capital Management LP Has $31,000 Position in Organon & Co. (NYSE:OGN)

Gladius Capital Management LP lifted its holdings in Organon & Co. (NYSE:OGN) by 65.1% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 2,176 shares of the company’s stock after acquiring an additional 858 shares during the quarter. Gladius Capital Management LP’s holdings in Organon & Co. were worth $31,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Cambridge Investment Research Advisors Inc. raised its position in Organon & Co. by 8.2% during the third quarter. Cambridge Investment Research Advisors Inc. now owns 24,159 shares of the company’s stock valued at $419,000 after acquiring an additional 1,838 shares in the last quarter. Raymond James & Associates grew its stake in Organon & Co. by 0.7% in the 3rd quarter. Raymond James & Associates now owns 345,810 shares of the company’s stock valued at $6,003,000 after buying an additional 2,354 shares during the last quarter. Raymond James Financial Services Advisors Inc. grew its position in shares of Organon & Co. by 13.7% in the third quarter. Raymond James Financial Services Advisors Inc. now owns 82,800 shares of the company’s stock valued at $1,437,000 after purchasing an additional 9,956 shares during the last quarter. New York State Teachers Retirement System boosted its stake in Organon & Co. by 3.7% during the 3rd quarter. New York State Teachers Retirement System now owns 289,905 shares of the company’s stock valued at $5,033,000 after purchasing an additional 10,281 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its position in Organon & Co. by 14.5% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 47,638 shares of the company’s stock worth $827,000 after buying an additional 6,046 shares during the period. Hedge funds and other institutional investors own 77.43% of the company’s stock.

Organon & Co. Price Performance

Shares of Organon & Co. stock traded up $0.15 during midday trading on Thursday, hitting $20.52. 2,023,524 shares of the company were exchanged, compared to its average volume of 2,713,194. The firm has a 50 day simple moving average of $18.41 and a 200-day simple moving average of $15.89. The firm has a market cap of $5.28 billion, a P/E ratio of 5.02, a PEG ratio of 0.88 and a beta of 0.81. Organon & Co. has a 52 week low of $10.84 and a 52 week high of $24.08.

Organon & Co. (NYSE:OGN) last announced its earnings results on Thursday, February 15th. The company reported $0.87 EPS for the quarter, topping the consensus estimate of $0.73 by $0.14. Organon & Co. had a negative return on equity of 259.73% and a net margin of 16.50%. The business had revenue of $1.60 billion for the quarter, compared to the consensus estimate of $1.55 billion. Equities research analysts expect that Organon & Co. will post 4.1 earnings per share for the current year.

Organon & Co. Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 13th. Investors of record on Monday, May 13th will be paid a dividend of $0.28 per share. This represents a $1.12 dividend on an annualized basis and a dividend yield of 5.46%. The ex-dividend date is Friday, May 10th. Organon & Co.’s dividend payout ratio (DPR) is 27.38%.

Analyst Ratings Changes

A number of brokerages recently issued reports on OGN. Piper Sandler boosted their target price on shares of Organon & Co. from $22.00 to $24.00 and gave the stock an “overweight” rating in a research report on Monday, April 29th. The Goldman Sachs Group lifted their target price on Organon & Co. from $18.00 to $20.00 and gave the stock a “neutral” rating in a research report on Friday, May 3rd.

Insider Transactions at Organon & Co.

In related news, insider Kirke Weaver purchased 2,720 shares of Organon & Co. stock in a transaction dated Thursday, February 22nd. The stock was bought at an average price of $18.36 per share, for a total transaction of $49,939.20. Following the completion of the acquisition, the insider now directly owns 15,181 shares of the company’s stock, valued at $278,723.16. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. 1.17% of the stock is owned by corporate insiders.

Organon & Co. Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.